

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Hiroyuki ABURATANI et al.
Serial No.: To Be Assigned
International
Appl. No.: PCT/JP2003/011318
Filed: September 4, 2003
For: **ANTIBODY AGAINST SECRETED N-TERMINAL
PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-
TERMINAL PEPTIDE OF GPC3**
Art Unit: To Be Assigned

MAIL STOP: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 4, 2005

**SUBMISSION OF SEQUENCE LISTING
AND STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825**


S IR:

In order to comply with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants provide herewith a Sequence Listing in computer readable form and in paper form (22 pages) in conformance with 37 C.F.R. §§ 1.821-1.825.

I hereby state that the sequence listing information recorded in computer readable form is identical to the written sequence listing submitted herewith, in accordance with 37 C.F.R. § 1.821(f).

Respectfully Submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, NY 10018
(212) 736-1940